Generics India's second-largest drugmaker, Dr Reddy's Laboratories (NYSE: RDY) posted full year ended March 31, 2012 financial results, with consolidated sales up 96.7 billion rupees ($1.8 billion at current exchange rates but over $2 billion at average rates for the reporting year), a rise of 30% on the previous fiscal year, driven by its key markets of North America and Russia in the global generics segment and Pharmaceutical Services and active ingredients segment. 14 May 2012